Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine.

dc.contributor.authorDávila-Fajardo, Cristina Lucía
dc.contributor.authorDíaz-Villamarín, Xando
dc.contributor.authorAntúnez-Rodríguez, Alba
dc.contributor.authorFernández-Gómez, Ana Estefanía
dc.contributor.authorGarcía-Navas, Paloma
dc.contributor.authorMartínez-González, Luis Javier
dc.contributor.authorDávila-Fajardo, José Augusto
dc.contributor.authorBarrera, José Cabeza
dc.date.accessioned2025-01-07T16:04:22Z
dc.date.available2025-01-07T16:04:22Z
dc.date.issued2019-04-01
dc.description.abstractThere is a special interest in the implementation of pharmacogenetics in clinical practice, although there are some barriers that are preventing this integration. A large part of these pharmacogenetic tests are focused on drugs used in oncology and psychiatry fields and for antiviral drugs. However, the scientific evidence is also high for other drugs used in other medical areas, for example, in cardiology. In this article, we discuss the evidence and guidelines currently available on pharmacogenetics for clopidogrel, warfarin, acenocoumarol, and simvastatin and its implementation in daily clinical practice.
dc.identifier.doi10.3390/genes10040261
dc.identifier.issn2073-4425
dc.identifier.pmcPMC6523655
dc.identifier.pmid30939847
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC6523655/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2073-4425/10/4/261/pdf?version=1555826694
dc.identifier.urihttps://hdl.handle.net/10668/27601
dc.issue.number4
dc.journal.titleGenes
dc.journal.titleabbreviationGenes (Basel)
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.organizationSAS - Hospital Universitario Virgen Macarena
dc.organizationSAS - Hospital Universitario San Cecilio
dc.organizationCentro Pfizer-Andalucía de Genómica e Investigación Oncológica (GENYO)
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.organizationSAS - Hospital Universitario San Cecilio
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectacenocoumarol
dc.subjectclopidogrel
dc.subjectpharmacogenetics
dc.subjectwarfarin
dc.subject.meshAcenocoumarol
dc.subject.meshAnticoagulants
dc.subject.meshAryl Hydrocarbon Hydroxylases
dc.subject.meshCardiovascular Diseases
dc.subject.meshClopidogrel
dc.subject.meshCytochrome P-450 CYP2C9
dc.subject.meshGuidelines as Topic
dc.subject.meshHumans
dc.subject.meshPharmacogenetics
dc.subject.meshPrecision Medicine
dc.subject.meshSimvastatin
dc.subject.meshWarfarin
dc.titlePharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number10

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC6523655.pdf
Size:
376.1 KB
Format:
Adobe Portable Document Format